Institution Directory

Clinical trials at Weill Cornell Medicine

Sites in New York, NY

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 12:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

781

Shown on this page

Current sort

Stored official records

Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Interventions: Clinical Observation, Crizotinib, Laboratory Biomarker Analysis; Other · Drug
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2036
U.S. locations: 1613
States / cities: Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 978 more

Conditions: Metastatic Prostate Cancer, Prostate Adenocarcinoma
Interventions: Abiraterone Acetate, Atezolizumab, Cabozantinib, Enzalutamide, Prednisone; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 575 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 36
States / cities: Tucson, Arizona • Duarte, California • Fullerton, California + 30 more

Conditions: Central Nervous System Tumor
Interventions: Not listed
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: Not listed
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer
Interventions: Letrozole 2.5Mg Tab, Palbociclib 125mg, Stereotactic Body Radiation Therapy (SBRT) (50GY in 5 fractions); Drug · Radiation
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 90 Years · Female only
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 3
States / cities: New York, New York

Conditions: Malignant Neoplasm of Breast Stage I
Interventions: Arm 1 600 cGY x 5 fractions, Arm 2 800 cGY x 3 fractions; Radiation
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 50 Years to 90 Years · Female only
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 4
States / cities: Los Angeles, California • New York, New York

Conditions: Unresectable Liver-limited Colorectal Metastases
Interventions: Liver transplant; Procedure
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2035
U.S. locations: 1
States / cities: New York, New York

Conditions: Adenoid Cystic Carcinoma, Any Solid Tumors Progressed After a Prior Immunotherapy, Esophageal Cancer, Head and Neck Cancers, Head and Neck Cancers - Nasopharyngeal, Head and Neck Cancers - Salivary Gland, Head and Neck Cancers - Throat, Head and Neck Cancers - Tonsils, Head and Neck Cancers Hypopharynx, Head and Neck Cancers Larynx, Head and Neck Cancers Lip, Head and Neck Cancers Nasopharynx, Head and Neck Cancers Oral Cavity, Head and Neck Cancers Oropharynx, Head and Neck Cancers Trachea, Head and Neck Carcinoma, Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma HNSCC, Lung Cancer, Lung Cancer (Locally Advanced or Metastatic), Mesothelioma, Non-Small Cell Lung Cancer, Pancreatic Cancer, Salivary Gland Carcinomas, Small Cell Lung Cancer ( SCLC )
Interventions: VMD-928 100 mg Tablet, VMD-928 Tablet and Pembrolizumab (200 mg); Drug
Lead sponsor: VM Oncology, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 14
States / cities: Santa Rosa, California • Hartford, Connecticut • Washington D.C., District of Columbia + 11 more

Conditions: Smoking Cessation
Interventions: Message Framing, Motivational Interviewing (MI), Nicotine Lozenge, Nicotine Replacement Therapy (NRT), saliva sample; Behavioral · Drug · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 50 Years to 80 Years
Enrollment: 807 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2026
U.S. locations: 18
States / cities: Los Angeles, California • Walnut Creek, California • La Grange, Georgia + 14 more

Conditions: Anal Fistula
Interventions: E-CEL UVEC; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2032
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Thromboembolic Pulmonary Hypertension, Pulmonary Arterial Hypertension, Pulmonary Hypertension
Interventions: Not listed
Lead sponsor: Pulmonary Hypertension Association, Inc.; Other
Eligibility: 0 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 52
States / cities: Phoenix, Arizona • Sacramento, California • San Francisco, California + 40 more

Conditions: COPD, Chronic Bronchitis, Chronic Obstructive Pulmonary Disease, Emphysema
Interventions: Not listed
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 40 Years to 80 Years
Enrollment: 2,981 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2031
U.S. locations: 14
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 10 more

Conditions: Urinary Urgency Incontinence
Interventions: Neuspera Implantable Sacral Nerve Stimulation System; Device
Lead sponsor: Neuspera Medical, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 331 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 31
States / cities: Encinitas, California • Los Angeles, California • San Diego, California + 27 more

About this Weill Cornell Medicine institution page

What this page lists: ClinicalTrials.gov records that list Weill Cornell Medicine in New York, NY as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Weill Cornell Medicine

Filter and sort this campus

Stored official records

Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

Tissue Collection for Drug Screening and Bioanalysis

Combined Immunotherapies in Metastatic ER+ Breast Cancer

Trial to Compare Radiation Fibrosis With Five Versus Three Fractions

Liver Transplantation for Unresectable Liver Limited Colorectal Metastases

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

Implementing Tobacco Treatment in Low Dose CT Lung Cancer Screening Sites

E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas

Pulmonary Hypertension Association Registry

Study of COPD Subgroups and Biomarkers

Neuspera's Implantable Sacral Nerve Stimulation System in Patients With Symptoms of Urinary Urgency Incontinence (UUI)

About this Weill Cornell Medicine institution page